EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular surveillance of resistance mutations in Plasmodium vivax clinical samples from southwestern India

Vishnu Teja Nallapati, A. R. Manoj, Sushma Belurkar, Naveenchandra Kulal, Prashanth Bhat, Nitin Gupta, Manjunath H. Hande, Kavitha Saravu

PLOS One · 17.11.2026 · 21 (11) · e0362585

DOI: 10.1371/journal.pone.0362585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.11.2026. Verfasst von Vishnu Teja Nallapati und 7 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasmodium vivax is a major cause of malaria in India, especially in the southwest, where chloroquine (CQ) followed by 14-day primaquine is the recommended treatment; however, antimalarial drug resistance poses a significant threat, prompting this study to investigate the molecular epidemiology of drug resistance in vivax malaria clinical samples from southwestern India. A total of 93 P. vivax malaria samples were collected from symptomatic adult patients at three sites in two districts: Kasturba Medical College, Manipal (13/07/2021–30/09/2024), Udupi District Hospital (07/07/2022–30/09/2024), and the Malaria Clinic, Mangaluru District Hospital (07/07/2022–30/09/2024). Extracted DNA was amplified and sequenced for resistance markers, including Pvcrt-o, Pvmdr1, Pvdhfr, and Pvdhps genes using Sanger sequencing, with genetic polymorphisms and haplotypes analyzed for resistance-associated mutations. In Pvcrt-o , the K10 AAG insertion was detected in 26% of samples; Pvmdr1 harbored M908L, T958M, Y976F, and F1076L mutations in 100%, 86.02%, 2.15%, and 84.94% of samples, respectively; Pvdhps showed A383G and A553G in 26.88% and 13.97%; while Pvdhfr exhibited S58R and S117N in 59.13% and 56.98%, with the double mutant (S58R+S117N) as the most prevalent haplotype. While mutations do not indicate complete CQ resistance, the Y976F mutation observed in two samples has been previously associated with reduced chloroquine susceptibility; these findings underscore the need for ongoing molecular surveillance and targeted antimalarial strategies.

Zitieren

APA

Nallapati, V. T., Manoj, A. R., Belurkar, S., Kulal, N., Bhat, P., Gupta, N., Hande, M. H., & Saravu, K. (2026). Molecular surveillance of resistance mutations in Plasmodium vivax clinical samples from southwestern India. PLOS One, 21(11), e0362585. https://doi.org/10.1371/journal.pone.0362585

Vancouver

Nallapati VT, Manoj AR, Belurkar S, Kulal N, Bhat P, Gupta N, et al. Molecular surveillance of resistance mutations in Plasmodium vivax clinical samples from southwestern India. PLOS One. 2026;21(11):e0362585. doi:10.1371/journal.pone.0362585

BibTeX
@article{Nallapati2026,
  author = {Nallapati, Vishnu Teja and Manoj, A. R. and Belurkar, Sushma and Kulal, Naveenchandra and Bhat, Prashanth and Gupta, Nitin and Hande, Manjunath H. and Saravu, Kavitha},
  title = {Molecular surveillance of resistance mutations in Plasmodium vivax clinical samples from southwestern India},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0362585},
  doi = {10.1371/journal.pone.0362585}
}
Kostenlos starten →